Skip to main content
. 2013 Jun 10;2013:151975. doi: 10.1155/2013/151975

Table 3.

Glycaemic control and weight gain in pregnant women receiving ILPS or NPH insulin.

ILPSg No. pt NPHg No. pt P
FCBG mg/dL (mmol/L)
 Before enrollment
  Total 100.7 ± 15.1
(5.6 ± 0.8)
21 100.6 ± 17.4
(5.6 ± 1.0)
25 ns
  T2DM 110.0 ± 7.8
(6.1 ± 0.4)
4 109.8 ± 15.8
(6.1 ± 0.9)
12 ns
  GDM 98.6 ± 15.8
(5.5 ± 0.9)
17 92.2 ± 14.5
(5.1 ± 0.8)
13 ns
 At the end of pregnancy
  Total 93.6 ± 13.4**  
(5.2 ± 0.7)
30 95.7 ± 10.8*  
(5.3 ± 0.6)
28 ns
  T2DM 89.2 ± 12.7*  
(4.9 ± 0.7)
4 95.5 ± 8.2°  
(5.3 ± 0.4)
13 ns
  GDM 94.3 ± 13.5*  
(5.2 ± 0.7)
26 95.8 ± 12.8*  
(5.3 ± 0.7)
15 ns
HbA1c% (mmol/L)
 At the end of pregnancy
  Total 5.4 ± 1.1
(36.0 ± 12.2)
34 5.3 ± 0.7
(34.4 ± 8.1)
33 ns
  T2DM 5.8 ± 1.1
(39.6 ± 12.6)
7 5.4 ± 0.7
(36.8 ± 8.2)
18 ns
  GDM 5.3 ± 1.1
(35.0 ± 12.1)
27 5.0 ± 0.6
(31.5 ± 7.2)
15 ns
Weight gain (kg)
 At the end of pregnancy
  Total 10.4 ± 6.1 53 9.9 ± 4.2 36 ns
  T2DM 12.0 ± 6.1 7 10.8 ± 4.9 18 ns
  GDM 10.2 ± 6.1 46 9.1 ± 3.3 18 ns

FCBG: fasting capillary blood glucose; T2DM: type 2 diabetes mellitus; GDM: gestational diabetes mellitus.

Paired t-test's P between preenrollment versus the end of pregnancy: *ns; **0.02; °0.004.